The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-05-19
DOI
10.1038/s41598-018-26496-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FBW7 -Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors
- (2017) Jingshan Tong et al. MOLECULAR CANCER THERAPEUTICS
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Biology and evolution of poorly differentiated neuroendocrine tumors
- (2017) David S Rickman et al. NATURE MEDICINE
- Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
- (2016) Sangjin Shin et al. BMC CANCER
- Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma
- (2016) Volker Ellenrieder et al. DIGESTION
- Pancreatic cancer: yesterday, today and tomorrow
- (2016) Daniel Ansari et al. Future Oncology
- The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
- (2016) Yasushi Taniguchi INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases
- (2016) Balasundaram Padmanabhan et al. JOURNAL OF BIOSCIENCES
- Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins
- (2016) Brigitt Raux et al. JOURNAL OF MEDICINAL CHEMISTRY
- FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
- (2016) J Tong et al. ONCOGENE
- The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
- (2016) Hyemin Kim et al. Oncotarget
- Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer
- (2016) Keisuke Yamamoto et al. Oncotarget
- Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains
- (2016) Akifumi Nakagawa et al. Scientific Reports
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies
- (2015) E Hessmann et al. ONCOGENE
- Perspectives in the treatment of pancreatic adenocarcinoma
- (2015) Angel Cid-Arregui WORLD JOURNAL OF GASTROENTEROLOGY
- Targeting BET bromodomains for cancer treatment
- (2015) Marie Jung et al. Epigenomics
- Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
- (2015) Lei-lei Fu et al. Oncotarget
- GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
- (2015) Krishan Kumar et al. Scientific Reports
- Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies
- (2015) Andrea Teague et al. Therapeutic Advances in Medical Oncology
- BETs abet Tam-R in ER-positive breast cancer
- (2014) Prasanna G Alluri et al. CELL RESEARCH
- Transport properties of pancreatic cancer describe gemcitabine delivery and response
- (2014) Eugene J. Koay et al. JOURNAL OF CLINICAL INVESTIGATION
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- Pancreatic cancer: A comprehensive review and update
- (2013) Thiruvengadam Muniraj et al. DM DISEASE-A-MONTH
- Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
- (2013) Olivier Mirguet et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development
- (2013) Yujun Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells
- (2009) Sung Pil Hong et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search